Clinical trial
Abatacept Versus Adalimumab Head-to-Head
NCT00929864 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00929864 |
|---|---|
| Title | Abatacept Versus Adalimumab Head-to-Head |
| Official title | A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Abatacept, Adalimumab |
| Enrollment | 869 |
| Start date | Oct 1, 2009 |
| Primary completion | Oct 1, 2011 |
| Completion | Nov 1, 2012 |
| First posted | Jun 30, 2009 |
| Last update posted | Feb 4, 2014 |
| Countries | Argentina, Canada, Chile, Peru, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: